ALS is currently clinically diagnosed by ruling out all other diseases that may cause symptoms similar to those presented by the patient. Iron Horse is developing the first diagnostic test for ALS that will rapidly determine if someone has the disease. Iron Horse is also developing markers of disease progression that will be useful to monitor disease progression and drug treatments during clinical trials.

Mild or repetitive injury to the brain is both a challenge to detect and difficult to determine when the injury has been resolved and the brain healed. Current clinical tools fail to detect or monitor the biologic basis of brain injury. Iron Horse is developing blood-based assays to directly detect injury to cells of the central nervous system. This test will be valuable to detect and monitor brain injury and concussion.



Iron Horse Diagnostics, Inc. Announced on July 18, 2016, a License Agreement with Global IVD Powerhouse EUROIMMUN AG for First to Market ALS Diagnostic Test

Iron Horse Dx announced on July 18, 2016, that they have signed a non-exclusive license agreement with Euroimmun Medizinische Labordiagnostika AG (Lübeck, Germany) to launch the first biological diagnostic test for Amyotrophic Lateral Sclerosis (“ALS”), more commonly known as Lou Gehrig’s Disease. To read the entire press release please click


Iron Horse Diagnostics, Inc. is a privately held molecular diagnostic company focused on the development and commercialization of novel tests to support the diagnosis and management of amyotrophic lateral sclerosis (ALS), traumatic brain injury (TBI), and other neurological diseases.

Iron Horse has developed and validated assays to measure protein-based signatures of disease. We expect to launch our first diagnostic test from a central reference laboratory in late 2015. This diagnostic is for ALS and uses cerebrospinal fluid samples. Our next product will be a blood-based diagnostic for ALS, with additional prognostic assays for ALS that can be used to monitor disease progression and test the effectiveness of drugs in clinical trials. Follow-up blood-based diagnostic assays will be for TBI and neuronal injury.


Iron Horse Diagnostics, Inc.